These findings suggest that sorafenib, by targeting SLC7A11, has the potential to enhance T-cell recognition and cytotoxicity in NPC cells, making it a promising therapeutic option for NPC. This evidence concerns the gene SLC7A11 and nasopharyngeal carcinoma.